TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy

Trial Profile

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGER-3
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 18 Oct 2017 Initial results of this study presented at the 18th World Conference on Lung Cancer.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 05 May 2016 According to Clovis Oncology media release, the FDA issued a CRL stating that the application is not ready for approval. Hence, company has terminated enrollment in all ongoing studies. Clovis has withdrawn its MAA for rociletinib previously filed with European regulatory authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top